论文部分内容阅读
目的观察和评价培哚普利治疗早期糖尿病肾病的临床疗效。方法 120例早期糖尿病肾病患者随机分为治疗组(60例)和对照组(60例)。两组患者在严格饮食控制和血糖、血压稳定控制情况下进行治疗。对照组继续维持原降糖、降压等糖尿病常规治疗;治疗组在对照组基础上给予口服培哚普利2～4mg,每日1次,共4周。观察两组治疗前后尿微量白蛋白(UMA)变化情况。结果治疗组治疗后UMA较治疗前明显下降(P<0.01),对照组治疗前后UMA无明显改变(P>0.05)。结论低剂量培哚普利可降低早期糖尿病肾病尿白蛋白的排泄,对早期糖尿病肾病有良好的保护及治疗作用。
Objective To observe and evaluate the clinical efficacy of perindopril in the treatment of early diabetic nephropathy. Methods 120 patients with early diabetic nephropathy were randomly divided into treatment group (60 cases) and control group (60 cases). Two groups of patients under strict diet control and blood glucose, blood pressure and stable control of treatment. The control group continued to maintain the routine diabetes mellitus such as hypoglycemic and antihypertensive treatment. The treatment group was given oral perindopril 2 ~ 4mg on the basis of the control group once a day for 4 weeks. Urinary microalbuminuria (UMA) changes before and after treatment were observed. Results The UMA in the treatment group was significantly lower than that before treatment (P <0.01), but there was no significant change in the UMA before and after treatment in the control group (P> 0.05). Conclusion Low-dose perindopril can reduce the excretion of urinary albumin in early stage of diabetic nephropathy, which has a good protection and therapeutic effect on early diabetic nephropathy.